Abstract
Hormone therapy is medically necessary for many transgender individuals. The U.S. Food and Drug Administration (FDA) and pharmaceutical companies' failure to guarantee a supply of injectable estrogen in 2016 and 2017 for transgender individuals is a violation of their right to comprehensive medical treatment, free of discrimination. A series of advocacy actions eventually led to all formulations of injectable estrogen being restored to market; however, long-term solutions to supply interruptions of injectable estrogen are needed. Long-term solutions should address the lack of federally funded research and, consequently, evidence-based practice on hormone therapy for gender affirmation.
Highlights
Hormone therapy is a medically necessary intervention for many transgender individuals.[1]
Patients report that injectable estradiol may offer faster, earlier breast development
According to the U.S Food and Drug Administration (FDA), a shortage of estradiol valerate began on August 10, 2016 and was fully resolved on June 12, 2017.6 the Callen-Lorde Community Health Center in New York City reported shortages in July 2016, when they received none of the 20 and 40 mg/mL formulations in their weekly drug shipment, and were told that the shortage would last until at least October 2016
Summary
Hormone therapy is a medically necessary intervention for many transgender individuals.[1] Studies have shown that gender affirmation through hormone therapy can improve psychological adjustment and quality of life, including reduced anxiety and depression, higher self-esteem, and improved social functioning.[1,2,3] The class of estrogen used for feminizing therapy is estradiol and is commonly delivered to transgender women through a patch, oral or sublingual tablet, or injection.[4]. There are no studies evaluating the benefits or risks of injectable estradiol, resulting in a lack of empirical data.[5] Patients report that injectable estradiol may offer faster, earlier breast development (personal communication, Dr Tim Cavanaugh [Director of Transgender Health] and Dr Alex Gonzalez [Medical Director], Fenway Health, 2016). Patients who do not achieve adequate feminization or adequate circulating blood concentrations of estradiol through oral and transdermal estrogen are often referred to injectable forms
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.